Feeder Cattle (FC)

Short interest for Franklin Covey gives investors a sense of the degree to which investors are betting on the decline of Franklin Covey's stock. Short interest data is updated every two weeks.

Franklin Covey Stock (NYSE:FC), Short Interest Report

Franklin Covey

Franklin Covey Co is a global company focused on organizational performance improvement. It focuses on providing time management and effectiveness training for individuals and corporations via online training as well as in-person workshops and events. The company provides training and consulting services in the areas of leadership, execution, productivity, trust, sales performance, customer loyalty, and educational improvement. It operates in the business segments of Direct Offices, Education practice, and International Licensees. The company derives revenue from providing training and consulting services, and through the selling of books, audio media, and other related products. It has a business presence in the United States and other international countries.

News

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

Movers

Trading Ideas

ALLO

APLT

CAAP

CPRX

TBPH

VYGR

U.S. stock futures were lower this morning, with the Dow Jones futures falling around 50 points on Friday.

Franklin Covey Shares Fall After Q1 Results, Joins Theravance Biopharma, Voyager Therapeutics And Other Big Stocks Moving Lower In Friday&#39;s Pre-Market Session

Earnings

ANGO

COST

With U.S. stock futures trading lower this morning on Friday, some of the stocks that may grab investor focus today are as follows:

Costco Wholesale, Constellation Brands And 3 Stocks To Watch Heading Into Friday

After-Hours Center

Franklin Covey Company (NYSE: FC) shares are trading lower in Thursday&#39;s after-hours session. The stock initially rose on news of the company&#39;s first-quarter earnings results but soon tumbled lower.

Franklin Covey Stock Rises After-Hours On Q1 Earnings Win Before Turning Lower

Franklin Covey Co

First Trust China AlphaDEX Fund

Firm Capital Apartment REIT

First Trust California Municipal High income ETF

First Capital Inc

FINECOBANK BANCA FINE SPA by Finecobank Banca Fineco SPA

FinecoBank SpA

First Community Bankshares, Inc. - Common Stock

First Community Bankshares Inc

FAST CASUAL CONCEPTS INC by FAST CASUAL CONCEPTS INC.

Fast Casual Concepts Inc

SPECTRAL CAPITAL CORP by Spectral Capital Corp.

Spectral Capital Corp

First Community Corporation - Common Stock

First Community Corp

FIRST COMMUNITY CORP (TN) by First Community Corp. (TN)

First Community Corp Tn

FIRST CMNTY CRP PR B (TN) by First Community Corp. (TN)

FIRST CMNTY CRP PR A (TN) by First Community Corp. (TN)

First Trust Income Opportunities ETF

FuelCell Energy Inc

FUELCELL ENERGY INC PFD B by FuelCell Energy, Inc.

First Commonwealth Financial Corporation Common Stock

First Commonwealth Financial Corp

FirstCash Holdings Inc

First Trust Exchange-Traded Fund First Trust S&P 500 Diversified Free Cash Flow ETF

First Trust Natural Gas ETF

FIRST COLOMBIA GLD CORP by First Colombia Gold Corp.

First Colombia Gold Corp

FCG INC by FCG, Inc.

FORECASTAGILITY CORP by Forecastagility Corporation

Forecastagility Corp

Georg Fischer AG

FIRST CHOICE HLTHCRE INC by First Choice Healthcare Solutions, Inc.

First Choice Healthcare Solutions Inc

FCCC Inc

Fidelity Cloud Computing ETF

FULL CIRCLE LITHIUM CORP by Full Circle Lithium Corp.

Full Circle Lithium Corp

FIRSTWAVE CLOUD TECH by Firstwave Cloud Technology Ltd.

FirstWave Cloud Technology Ltd

FIRM CAP MTG INVST CORP by Firm Capital Mortgage Investment Corp

Firm Capital Mortgage Investment Corp

FTI Consulting Inc

First Citizens BancShares, Inc. - Class A Common Stock

First Citizens BancShares Inc

FIRST CTZNS BANCSHS B by First Citizens BancShares, Inc.

First Citizens BancShares, Inc. - 5.625% Non-Cumulative Perpetual Preferred Stock, Series C

First Citizens BancShares, Inc. - Depositary Shares Each Representing a 1/40th Interest in a Share of 5.375% Non-Cumulative Perpetual Preferred Stock, Series A

Four Corners Inc. Com

abrdn Global Income Fund, Inc. Common Stock

abrdn Global Income Fund Inc

1ST COLONIAL BANCORP INC by 1st Colonial Bancorp, Inc.

1st Colonial Bancorp Inc

COMPAGNIE DE L ODET by COMPAGNIE DE L ODET

Compagnie de l`Odet

Fidelity MSCI Communication Services Index ETF

SpaceFalcon

Fidelity Corporate Bond ETF

FIRST CAPITAL BNCSHS SC by First Capital Bancshares, Inc.

First Capital Bancshares Inc

Fidelity Stocks for Inflation ETF

Four Corners Property Trust, Inc. Common Stock

Four Corners Property Trust Inc

FLETCHER BLDG SP/ADR by Fletcher Building Ltd.

Fletcher Building Ltd

FRANKLIN CREDIT MGMT CORP by Franklin Credit Management Corp.

Franklin Credit Management Corp

ICHIGO OFFICE REIT INVT by Ichigo Office Reit Invt Corp.

Ichigo Office REIT Investment Corp

Crescent Capital BDC, Inc. 5.00% Notes due 2026

Federated Hermes ETF Trust Federated Hermes Short Duration Corporate ETF

FOCUS GRAPHITE INC by Focus Graphite, Inc.

Focus Graphite Inc

FreeCast, Inc.

FOCUS MINERALS LTD by Focus Minerals Ltd.

Focus Minerals Ltd

First Trust Senior Floating Rate Income Fund II Common Shares of Beneficial Interest

First Trust Senior Floating Rate Income Fund II

FirmaChain

Factom

Fact Inc

First Trust Lunt U.S. Factor Rotation ETF

FARM CRED BK PFD B SER 2 by Farm Credit Bank

Farm Credit Bank of Texas

Tidal ETF Trust II Pinnacle Focused Opportunities ETF

FISSION URANIUM CORP ORD by Fission Uranium Corp.

Fission Uranium Corp

Focus Universal Inc

First Trust SSI Strategic Convertible Securities ETF

Freeport-McMoRan Inc

First Capital REIT

Buybacks

Franklin Covey Board Approves $50M Purchase Plan

Barrington Research analyst Alexander Paris maintains Franklin Covey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>) with a Outperform and maintains $45 price target.

Price Target

Analyst Ratings

Barrington Research Maintains Outperform on Franklin Covey, Maintains $45 Price Target

In the latest quarter, 4 analysts provided ratings for Franklin Covey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>), showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $62.5, with a high estimate of $95.00 and a low estimate of $45.00. This current average represents a 19.35% decrease from the previous average price target of $77.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1711645261_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Franklin Covey. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nehal Chokshi</td>
<td>Northland Capital Markets</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$95.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$55.00</td>
<td>-</td>
</tr>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$55.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Franklin Covey. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Franklin Covey compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Franklin Covey's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Franklin Covey's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/FC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Franklin Covey analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Franklin Covey's Background</h2>
Franklin Covey Co is a global company focused on organizational performance improvement. It focuses on providing time management and effectiveness training for individuals and corporations via online training as well as in-person workshops and events. The company provides training and consulting services in the areas of leadership, execution, productivity, trust, sales performance, customer loyalty, and educational improvement. It operates in the business segments of Direct Offices, Education practice, and International Licensees. The company derives revenue from providing training and consulting services, and through the selling of books, audio media, and other related products. It has a business presence in the United States and other international countries.
<h3>Franklin Covey's Financial Performance</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Franklin Covey's financials over 3 months reveals challenges. As of 30 November, 2023, the company experienced a decline of approximately -1.4% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Franklin Covey's net margin excels beyond industry benchmarks, reaching 7.09%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Franklin Covey's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.5% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Franklin Covey's ROA excels beyond industry benchmarks, reaching 2.09%. This signifies efficient management of assets and strong financial health.
Debt Management: Franklin Covey's debt-to-equity ratio is below the industry average at 0.19, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings For Franklin Covey

Northland Capital Markets analyst Nehal Chokshi maintains Franklin Covey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>) with a Outperform and lowers the price target from $100 to $95.

Northland Capital Markets Maintains Outperform on Franklin Covey, Lowers Price Target to $95

Barrington Research analyst Alexander Paris maintains Franklin Covey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>) with a Outperform and lowers the price target from $55 to $45.

Barrington Research Maintains Outperform on Franklin Covey, Lowers Price Target to $45

Franklin Covey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>) reported its Q2 earnings results on Wednesday, March 27, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Franklin Covey beat estimated earnings by 20.0%, reporting an EPS of $0.06 versus an estimate of $0.05.
Revenue was down $420 thousand from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.13 which was followed by a 3.0% increase in the share price the next day.
Here's a look at Franklin Covey's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.23</td>
<td>0.48</td>
<td>0.22</td>
<td>0.13</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.36</td>
<td>0.49</td>
<td>0.32</td>
<td>0.12</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>65.88M</td>
<td>81.60M</td>
<td>69.62M</td>
<td>62.40M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>68.40M</td>
<td>77.95M</td>
<td>71.44M</td>
<td>61.76M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Franklin Covey <a href="https://www.benzinga.com/quote/FC/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: Franklin Covey Q2 Earnings

Franklin Covey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.05 by 20 percent. This is a 50 percent decrease over earnings of $0.12 per share from the same period last year. The company reported quarterly sales of $61.34 million which missed the analyst consensus estimate of $62.02 million by 1.10 percent. This is a 0.68 percent decrease over sales of $61.76 million the same period last year.

Franklin Covey Q2 EPS $0.06 Beats $0.05 Estimate, Sales $61.34M Miss $62.02M Estimate

<h3>Companies Reporting Before The Bell</h3>
&bull; Local Bounti (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOCL#NYSE">LOCL</a>) is projected to report quarterly loss at $2.41 per share on revenue of $8.70 million.
&bull; REE Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REE#NASDAQ">REE</a>) is estimated to report quarterly loss at $2.38 per share on revenue of $1.35 million.
&bull; Precision BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTIL#NASDAQ">DTIL</a>) is projected to report quarterly loss at $2.05 per share on revenue of $12.48 million.
&bull; Edap TMS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDAP#NASDAQ">EDAP</a>) is expected to report quarterly loss at $0.05 per share on revenue of $19.66 million.
&bull; Vanguard Extended Duration Treasury ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDV#NYSE">EDV</a>) is expected to report earnings for its fourth quarter.
&bull; Cellectar Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) is likely to report earnings for its fourth quarter.
&bull; Gamida Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GMDA#NASDAQ">GMDA</a>) is projected to report quarterly loss at $0.15 per share on revenue of $1.06 million.
&bull; PDS Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDSB#NASDAQ">PDSB</a>) is likely to report earnings for its fourth quarter.
&bull; Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) is projected to report earnings for its fourth quarter.
&bull; Syros Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRS#NASDAQ">SYRS</a>) is estimated to report quarterly loss at $1.14 per share on revenue of $2.00 million.
&bull; Lands&#39; End (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LE#NASDAQ">LE</a>) is expected to report quarterly earnings at $0.21 per share on revenue of $502.71 million.
&bull; Cintas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTAS#NASDAQ">CTAS</a>) is projected to report quarterly earnings at $3.58 per share on revenue of $2.39 billion.
&bull; GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) is projected to report earnings for its fourth quarter.
&bull; Sonida Senior Living (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDA#NYSE">SNDA</a>) is projected to report earnings for its fourth quarter.
&bull; UniFirst (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNF#NYSE">UNF</a>) is projected to report quarterly earnings at $1.42 per share on revenue of $587.84 million.
<h3>Companies Reporting After The Bell</h3>
&bull; Creative Media (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCT#NASDAQ">CMCT</a>) is estimated to report quarterly loss at $0.48 per share on revenue of $30.20 million.
&bull; Draganfly (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPRO#NASDAQ">DPRO</a>) is likely to report earnings for its fourth quarter.
&bull; VNET Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNET#NASDAQ">VNET</a>) is projected to report quarterly loss at $0.18 per share on revenue of $279.03 million.
&bull; RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) is estimated to report quarterly earnings at $1.67 per share on revenue of $777.48 million.
&bull; American Shared Hospital (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AMS#AMEX">AMS</a>) is estimated to report quarterly earnings at $0.02 per share on revenue of $5.19 million.
&bull; Cosan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSAN#NYSE">CSAN</a>) is likely to report quarterly earnings at $0.16 per share on revenue of $7.45 billion.
&bull; Greenidge Generation Hldg (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GREE#NASDAQ">GREE</a>) is estimated to report quarterly earnings at $0.25 per share on revenue of $26.70 million.
&bull; Gaia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAIA#NASDAQ">GAIA</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $21.00 million.
&bull; Allied Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGAE#NASDAQ">AGAE</a>) is projected to report earnings for its fourth quarter.
&bull; Jefferies Financial Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JEF#NYSE">JEF</a>) is likely to report quarterly earnings at $0.75 per share on revenue of $1.52 billion.
&bull; LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) is expected to report quarterly loss at $1.73 per share on revenue of $2.28 million.
&bull; H.B. Fuller (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUL#NYSE">FUL</a>) is projected to report quarterly earnings at $0.64 per share on revenue of $825.03 million.
&bull; Sprinklr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXM#NYSE">CXM</a>) is likely to report quarterly earnings at $0.09 per share on revenue of $188.73 million.
&bull; Dynagas LNG Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLNG#NYSE">DLNG</a>) is expected to report quarterly earnings at $0.30 per share on revenue of $38.21 million.
&bull; Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) is estimated to report quarterly loss at $0.33 per share on revenue of $2.48 million.
&bull; Celcuity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELC#NASDAQ">CELC</a>) is expected to report earnings for its fourth quarter.
&bull; BioCardia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) is estimated to report quarterly loss at $0.11 per share on revenue of $90 thousand.
&bull; Consolidated Water Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWCO#NASDAQ">CWCO</a>) is likely to report quarterly earnings at $0.44 per share on revenue of $45.25 million.
&bull; Silver Spike Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSIC#NASDAQ">SSIC</a>) is projected to report quarterly earnings at $0.27 per share on revenue of $3.37 million.
&bull; Urban-gro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) is estimated to report quarterly loss at $0.13 per share on revenue of $28.94 million.
&bull; PLBY Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLBY#NASDAQ">PLBY</a>) is estimated to report quarterly loss at $0.14 per share on revenue of $32.27 million.
&bull; Usio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USIO#NASDAQ">USIO</a>) is projected to report quarterly earnings at $0.00 per share on revenue of $20.43 million.
&bull; Franklin Covey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>) is estimated to report quarterly earnings at $0.05 per share on revenue of $62.02 million.
&bull; Super League Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLE#NASDAQ">SLE</a>) is estimated to report quarterly loss at $1.20 per share on revenue of $9.30 million.
&bull; Spectral AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDAI#NASDAQ">MDAI</a>) is estimated to report quarterly loss at $0.40 per share on revenue of $4.60 million.
&bull; Strata Skin Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSKN#NASDAQ">SSKN</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $10.01 million.
&bull; Verint Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNT#NASDAQ">VRNT</a>) is estimated to report quarterly earnings at $0.97 per share on revenue of $263.12 million.
&bull; Eastside Distilling (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EAST#NASDAQ">EAST</a>) is projected to report quarterly loss at $0.90 per share on revenue of $3.68 million.
&bull; Braze (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) is likely to report quarterly loss at $0.05 per share on revenue of $124.86 million.
&bull; Oncology Institute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOI#NASDAQ">TOI</a>) is expected to report quarterly loss at $0.11 per share on revenue of $82.04 million.
&bull; Aqua Metals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQMS#NASDAQ">AQMS</a>) is expected to report quarterly loss at $0.05 per share on revenue of $50 thousand.
&bull; Kingstone Companies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KINS#NASDAQ">KINS</a>) is estimated to report quarterly loss at $0.08 per share on revenue of $29.65 million.
&bull; MillerKnoll (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLKN#NASDAQ">MLKN</a>) is projected to report quarterly earnings at $0.44 per share on revenue of $909.50 million.
&bull; Rumble (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUM#NASDAQ">RUM</a>) is likely to report quarterly loss at $0.22 per share on revenue of $28.13 million.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

AGAE

AQMS

BCDA

BRZE

CELC

CLRB

CMCT

CSAN

CTAS

CWCO

DLNG

DPRO

DRRX

DTIL

EAST

EDAP

GAIA

GLYC

GMDA

GREE

KINS

LGMK

LOCL

MDAI

MLKN

PDSB

PLBY

SNDA

SSIC

SSKN

SYRS

UGRO

USIO

VNET

VRNT

Earnings Scheduled For March 27, 2024

Franklin Covey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>) is set to give its latest quarterly earnings report on Wednesday, 2024-03-27. Here's what investors need to know before the announcement.
Analysts estimate that Franklin Covey will report an earnings per share (EPS) of $0.05. 
Franklin Covey bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.13, which was followed by a 3.28% increase in the share price the next day.
Here's a look at Franklin Covey's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.23</td>
<td>0.48</td>
<td>0.22</td>
<td>0.13</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.36</td>
<td>0.49</td>
<td>0.32</td>
<td>0.12</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>-9.0%</td>
<td>26.0%</td>
<td>-18.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1711461711_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Franklin Covey were trading at $38.9 as of March 25. Over the last 52-week period, shares are down 12.14%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/FC/earnings">To track all earnings releases for Franklin Covey visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For Franklin Covey

Barrington Research analyst Alexander Paris reiterates Franklin Covey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>) with a Outperform and maintains $55 price target.

Reiteration

Barrington Research Reiterates Outperform on Franklin Covey, Maintains $55 Price Target

U.S. stock futures were lower this morning, with the Dow Jones futures falling around 50 points on Friday.
Shares of Franklin Covey Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fc#NYSE">FC</a>) fell sharply in pre-market trading after the company reported <a href="https://www.benzinga.com/news/earnings/24/01/36502545/franklin-covey-stock-rises-after-hours-on-q1-earnings-win-before-turning-lower">results for its first quarter.</a>
The company reported quarterly earnings of 36 cents, exceeding estimates of 23 cents per share. Revenue of $68.40 million clocked in above the analyst consensus estimate of $65.88 million.
Franklin Covey affirmed its outlook that adjusted EBITDA will grow to between $54.5 million and $58 million in constant currency in the full year 2024, versus $48.1 million achieved in the same period in 2023.
Franklin Covey shares fell 4.1% to $37.75 in pre-market trading.
Here are some big stocks recording losses in today&rsquo;s pre-market trading session.
<ul>
<li>Applied Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aplt#NASDAQ">APLT</a>) shares declined 30.1% to $2.65 in pre-market trading after reporting topline results from ARISE-HF Phase 3 study of AT-001 in diabetic cardiomyopathy.</li>
<li>Theravance Biopharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tbph#NASDAQ">TBPH</a>) shares fell 18.4% to $9.40 in pre-market trading after the company announced results from Phase 4 YUPELRI PIFR-2 study. The company said study did not show a statistically significant difference between yupelri and spiriva handihaler on primary endpoint.</li>
<li>Voyager Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vygr#NASDAQ">VYGR</a>) shares tumbled 16.6% to $9.04 in pre-market trading. Voyager Therapeutics priced its public offering of 7,777,778 common shares at $9 per share.</li>
<li>Medical Properties Trust, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mpw#NYSE">MPW</a>) shares dipped 14.2% to $4.29 in pre-market trading after the company issued an update on Steward Health Care. Keybanc analyst Austin Wurschmidt downgraded Medical Properties Trust from Overweight to Sector Weight.</li>
<li>Catalyst Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cprx#NASDAQ">CPRX</a>) shares fell 12.2% to $15.03 in pre-market trading after announcing a proposed public offering of common stock.</li>
<li>Allogene Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/allo#NASDAQ">ALLO</a>) shares declined 12.1% to $2.98 in pre-market trading. Allogene Therapeutics and Foresight Diagnostics disclosed a partnership to develop MRD-based in-vitro diagnostic for use in ALPHA3, the first pivotal trial for frontline consolidation in large B-cell lymphoma.</li>
<li>Dyne Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dyn#NASDAQ">DYN</a>) shares fell 4.6% to $18.50 in pre-market trading. Dyne Therapeutics priced its $300 million public offering of 17.15 million common stock at $17.50 per share.</li>
<li>Corporaci&oacute;n Am&eacute;rica Airports S.A. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/caap#NYSE">CAAP</a>) shares declined 4.4% to $15.00 in pre-market trading.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/01/36484759/fear-greed-index-moves-to-greed-zone-nasdaq-tumbles-for-4th-consecutive-day"> Fear &amp; Greed Index Moves To &#39;Greed&#39; Zone; Nasdaq Tumbles For 4th Consecutive Day </a>
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>

Franklin Covey Shares Fall After Q1 Results, Joins Theravance Biopharma, Voyager Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session

With U.S. stock futures trading lower this morning on Friday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Constellation Brands, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/stz#NYSE">STZ</a>) to report quarterly earnings at $3.00 per share on revenue of $2.54 billion before the opening bell. Constellation shares gained 0.8% to $244.30 in after-hours trading.</li>
<li>Franklin Covey Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fc#NYSE">FC</a>) reported upbeat sales for its first quarter on Thursday. Franklin Covey shares fell 6% to $37.01 in the after-hours trading session.</li>
<li>Analysts are expecting The Greenbrier Companies, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gbx#NYSE">GBX</a>) to earn 73 cents per share on revenue of $849.94 million for the latest quarter. The company will release earnings before the markets open. Greenbrier shares gained 0.02% to $44.35 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a> 
<ul>
<li>Costco Wholesale Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cost#NASDAQ">COST</a>) reported net sales of $26.15 billion for the retail month of December, representing a 9.9% increase from $23.80 billion last year. Costco shares gained 1% to $654.80 in the after-hours trading session.</li>
<li>Analysts expect AngioDynamics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ango#NASDAQ">ANGO</a>) to post a quarterly loss at 7 cents per share on revenue of $82.04 million before the opening bell. AngioDynamics shares gained 0.7% to $7.80 in after-hours trading.</li>
</ul>
&nbsp;
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/01/36489301/wall-streets-most-accurate-analysts-say-buy-these-3-energy-stocks-delivering-high-divide"> Wall Street&#39;s Most Accurate Analysts Say Buy These 3 Energy Stocks Delivering High-Dividend Yields </a>

Franklin Covey Company&nbsp;(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fc#NYSE">FC</a>) shares are trading lower in Thursday&#39;s after-hours session. The stock initially rose on news of the company&#39;s first-quarter earnings results but soon tumbled lower.
Here&#39;s an overview of the metrics that are <a href="https://www.benzinga.com/pressreleases/24/01/b36499414/franklin-covey-reports-strong-financial-results-to-start-fiscal-2024">behind the price movement</a>.
What To Know: The company reported quarterly earnings of 36 cents, exceeding estimates of 23 cents per share, a 12.5% increase over earnings of 32 cents per share from the same period last year.
Revenue of $68.40 million clocked in above the analyst consensus estimate of $65.88 million, marking a 1.40% decrease over sales of $69.37 million the same period last year.
Additionally, cash flows from operating activities rose to $17.4 Million, compared to $3.0 Million in the same period last year.
Franklin Covey affirmed its outlook that adjusted EBITDA will grow to between $54.5 million and $58 million in constant currency in the full year 2024, versus&nbsp; $48.1 million achieved in the same period in 2023.
Paul Walker, president and CEO, weighed in on the results, saying, &quot;Although our results were essentially even with last year&#39;s first quarter, we are pleased that both revenue and Adjusted EBITDA came in stronger than forecasted.&quot;
Walker added: &quot;While we also expect second-quarter revenue to be about even with the prior year, there are several key factors we expect will significantly strengthen in the back half of the year. These include a high flow-through of revenue, which will drive the growth in Adjusted EBITDA to our fiscal 2024 target of between $54.5 million and $58 million.&quot;
Related Link: <a href="https://www.benzinga.com/news/24/01/36501250/voyager-therapeutics-stock-tanked-after-hours-heres-why">Voyager Therapeutics Stock Tanked After-Hours - Here&#39;s Why</a>
FC Price Action: Shares of Franklin Covey were down 5.51% at $37.20&nbsp;in the after-hours session at the time of publication, according to <a href="http://pro.benzinga">Benzinga Pro</a>.
Photo:&nbsp;<a href="https://pixabay.com/users/stubaileyphoto-19245286/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=5772300">Stuart Bailey</a> from <a href="https://pixabay.com//?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=5772300">Pixabay</a>

WIIM

Franklin Covey shares are trading higher after the company reported Q1 financial results.

<h3>Gainers</h3>
<ul>
<li>Franklin Covey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>) shares moved upwards by 11.8% to $44.0 during Thursday's after-market session. The market value of their outstanding shares is at $584.1 million. As per the press release, Q1 earnings came out today. </li>
<li>Mesa Air Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESA#NASDAQ">MESA</a>) shares increased by 4.3% to $0.93. The company's market cap stands at $37.9 million. </li>
<li>AgEagle Aerial Sys (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UAVS#AMEX">UAVS</a>) stock rose 4.27% to $0.1. The company's market cap stands at $12.5 million. </li>
<li>SOS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOS#NYSE">SOS</a>) shares moved upwards by 4.21% to $4.95. The market value of their outstanding shares is at $45.4 million. </li>
<li>374Water (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCWO#NASDAQ">SCWO</a>) shares increased by 4.09% to $1.27. The company's market cap stands at $168.4 million. </li>
<li>Royalty Management Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMCO#NASDAQ">RMCO</a>) shares moved upwards by 3.7% to $2.24. The market value of their outstanding shares is at $31.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Addentax Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXG#NASDAQ">ATXG</a>) stock fell 4.8% to $1.18 during Thursday's after-market session. The company's market cap stands at $5.0 million. </li>
<li>Aqua Metals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQMS#NASDAQ">AQMS</a>) shares declined by 3.92% to $0.66. The company's market cap stands at $71.5 million. </li>
<li>Safe &amp; Green Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGBX#NASDAQ">SGBX</a>) shares decreased by 3.77% to $0.44. The market value of their outstanding shares is at $7.2 million. </li>
<li>Northann (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NCL#AMEX">NCL</a>) stock declined by 3.14% to $1.08. The market value of their outstanding shares is at $23.0 million. </li>
<li>Nuburu (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BURU#AMEX">BURU</a>) shares fell 2.92% to $0.16. The company's market cap stands at $5.8 million. </li>
<li>Castor Maritime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTRM#NASDAQ">CTRM</a>) stock declined by 2.78% to $0.58. The company's market cap stands at $56.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATXG

BURU

CTRM

MESA

Nuveen Insured California Premium Fund Ii

RMCO

SCWO

SGBX

UAVS

12 Industrials Stocks Moving In Thursday's After-Market Session

Fiscal 2024 Guidance and Outlook
Driven by the continued strength and strategic durability of its All Access Pass and Leader in Me membership subscriptions, first quarter results that were better-than-expectations, and the expectation of a strong second half of the year, the Company affirms its guidance for fiscal 2024 that Adjusted EBITDA will increase to between $54.5 million and $58.0 million in constant currency, compared with the $48.1 million of Adjusted EBITDA achieved in fiscal 2023. The Company expects to achieve this growth while continuing to make additional growth investments. While the Company is alert to potential macroeconomic disruptions that could adversely impact its future operating results, the Company remains confident in the strength of its subscription offerings, which have driven Franklin Covey's growth across recent years and are expected to drive the Company's continued growth in fiscal 2024 and future years.

Guidance

Franklin Covey  Affirms Its Guidance For Fiscal 2024 That Adjusted EBITDA Will Increase To Between $54.5M-$58M In Constant Currency, Compared With The $48.1M YoY

Franklin Covey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>) reported quarterly earnings of $0.36 per share. This is a 12.5 percent increase over earnings of $0.32 per share from the same period last year. The company reported quarterly sales of $68.40 million which beat the analyst consensus estimate of $65.88 million by 3.83 percent. This is a 1.40 percent decrease over sales of $69.37 million the same period last year.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Franklin Covey Stock (NYSE:FC), Short Interest Report

People Also Watch